Korea gates commercial cosmetics imports through a registrant. An importer registers as a responsible distributor under Article 3 of the Cosmetics Act, files a clearance report before customs release, and tests each batch before sale. On 17 September two agencies announced that roughly 97,000 counterfeit units had moved through Coupang and Naver over fourteen months. None of those controls failed. None of them applied. Central Investigation Unit for Drug and Food Crimes at the Ministry of Food and Drug Safety, briefs reporters on the arrest of brokers distributing counterfeit Chinese cosmetics and health supplements, at the Seoul Regional Office of Food and Drug Safety What did the two agencies actually announce? The trademark special judicial police of the Intellectual Property Administration and the Central Investigation Division for Harmful Products at the Ministry of Food and Drug Safety referred a distribution broker to prosecutors. The announcement covers a fourteen-month window running from October 2024 to November 2025, during which the broker sold 61 counterfeit product types, roughly 83,000 units, for 4.5 billion won (about $3.25 million). A further 87 types, roughly 14,000 units with a stated market value of 1.3 billion won (about $940,000), were seized unsold at a logistics warehouse in Cheongju, North Chungcheong. All won figures in this article convert at 1,383.3 per US dollar, the Seoul close on 18 September 2026. The mechanics are plain. The counterfeits were produced by a manufacturer in Shenzhen, brought into Korea as international express cargo and overseas parcels, consolidated at the Cheongju warehouse, listed on Coupang and Naver as authentic, and delivered to buyers by domestic courier. The agencies stated that this was the first case in which their two units ran a joint investigation to map a counterfeit distribution route, after receiving a tip that fakes were circulating on the platforms. One figure in the announcement does not reconcile. The headline aggregate market value is given as 5.4 billion won, while the two component figures released alongside it — 4.5 billion sold and 1.3 billion seized — sum to 5.8 billion. This article uses the components. The broker sold 83,000 units before investigators reached the 14,000 still sitting in the Cheongju warehouse. Why does the list of copied brands matter more than the total? Twenty-eight of the 61 types were cosmetics. Two of the names are the ones a counterfeit table always carries: Estée Lauder and SK-II, prestige products with the price gap that has funded counterfeiting for decades. The other three are not. Celladix, Kahi and Beauty of Joseon are Korean brands, and none of them sells at a prestige price. That combination is the substantive finding. Copying a prestige serum is an arbitrage on margin — the counterfeiter captures the gap between a cheap formula and an expensive label. Copying a mid-priced Korean essence captures almost none of that gap. What it captures instead is recognition and velocity: a label that converts at scale on an open marketplace, in a category where consumers buy on reputation and repurchase quickly. Once counterfeiting economics run on turnover rather than unit margin, the protected zone is no longer defined by price. The same announcement covered counterfeit health functional foods, including copies of a Denps probiotic line and a Korea Eundan multivitamin, and counterfeit Brita filter cartridges whose stated country of origin had been changed from China to Germany. The relabeling on the filter cartridges is the same operation as the label on the cosmetics, performed on a different product category. Beauty of Joseon is an export brand. Counterfeits of it were manufactured in Shenzhen and sold to Korean consumers inside Korea. The counterfeiting of K-beauty has stopped being a problem that happens to Korean brands in foreign markets. What did the laboratory find inside the products? Twelve of the seized functional cosmetics and health functional foods were analysed. In the cosmetics, the functional ingredients tied to the claims printed on the packaging were not detected. In the supplements, the marker substances used to verify the declared ingredients were not detected either. The agencies stated that the products carry no assurance of the claimed function and none of safety. A functional cosmetic, under Article 2 of the Cosmetics Act, is one that makes one of eleven defined claims — whitening, wrinkle improvement, ultraviolet protection, hair loss relief, acne care and others. Article 4 requires that such a product pass a review or, for formulations matching an already approved specification, a report, supported by efficacy data and human application data. The claim is the regulated object. In an ordinary consumer good, a missing ingredient is a quality defect. In a functional cosmetic it is the entire product. The state did not approve a jar; it approved a sentence, on the condition that a specific molecule sat behind it. The laboratory result says the sentence shipped without the molecule. The physical differences investigators recorded were narrow: packaging material, printed content, container shape and size, and the formulation's texture and colour. Those are the tells a buyer would have to catch on a product photograph, before purchase, against a genuine reference they do not have in hand. Five steps carried the goods from Shenzhen to a Korean doorstep, and not one of them is the step at which Korean cosmetics law attaches. How did 97,000 units reach a market with a licensed import gate? A declared commercial cosmetics import in Korea runs through a fixed sequence. The importer must hold a responsible distributor registration — the licence that makes a company answerable for the quality and safety of what it puts into the market. Before customs release it files a standard clearance report through an approved electronic provider, attaching the registration certificate, a manufacturing certificate and a free-sale certificate from the origin market. After release, each production batch is quality tested, and only batches that pass are permitted to be sold. The broker entered none of that sequence. International express cargo and the overseas parcel channel are built around consignments destined for personal use, cleared at item level and at low value, on the assumption that the recipient is the end consumer. Korea does exclude functional cosmetics from list clearance, the simplified regime that releases low-value parcels on a manifest alone, which pushes them to a normal import declaration. That exclusion is the closest thing to a product-level check on the parcel path, and it is a clearance formality, not a quality one. This is the structural point. Every control in Korea's cosmetics regime attaches to a registered entity. Registration, clearance reporting and batch testing all presuppose that somebody has put their name on the goods. A parcel has a recipient, not a registrant. A marketplace listing has a seller account, not a registrant. The chain ran for fourteen months in the space between those two facts. The penalty structure records the same asymmetry. Operating as a cosmetics responsible distributor without registration carries up to three years' imprisonment or a fine of up to 30 million won under Article 36 of the Cosmetics Act. Trademark infringement carries up to seven years or up to 100 million won under Article 230 of the Trademark Act. The heavier sanction attaches to the borrowed name, not to the absent ingredient. What does a pre-market approval control once the label is printed offshore? Korea's functional cosmetics system is a pre-market claim approval regime, and a strict one. A dossier goes in, efficacy and human application data are assessed, and a right to make a specific claim comes out. The regime is well suited to the market it was designed for, in which the party making the claim is a registered domestic entity that can be inspected, audited and deregistered. Printing is the weak link, and printing has been offshore for years. Once packaging carrying an approved claim can be reproduced by any printer with a photograph of the original, the approval controls a document rather than a product. The enforcement surface of the entire regime is the registrant, and the counterfeit supply chain is constructed precisely to have no registrant. That is why this case surfaced through a tip and a trademark investigation rather than through cosmetics surveillance. Post-market inspection samples products at registered sellers. Batch testing tests batches that were declared. Neither instrument looks at 83,000 units that were never declared to exist. How large is this against what customs stops at the border? The Korea Customs Service detected 117,005 counterfeit items bearing Korean brands at the clearance stage in calendar 2025, announced in January 2026. Cosmetics were the largest single category at 36%, ahead of toys and stationery at 33%. Goods shipped from China accounted for 97.7% of the total. A special enforcement drive run from 4 May to 30 June 2026 gives the second lens. Clearance-stage seizures in that window reached 452,927 items, against roughly 177,000 in the same period of 2025. Foreign brands accounted for 448,183 of those and Korean brands for 4,744. By entry channel, general cargo carried 315,216 items, express and postal consignments 127,468, and traveller baggage 10,243. The investigative arm of the same drive booked 14 cases covering 3.65 million items with a stated market value of 153 billion won (about $111 million). Across all of 2025, the value of intellectual property infringing goods seized reached 278.9 billion won (about $202 million), up 64% from 170.5 billion won the year before. Set against those totals, 97,000 units is rounding error. That is the reading that matters. The border apparatus is calibrated to intercept consolidated volume, and it does — millions of units, hundreds of billions of won. This shipment never presented as volume. It arrived in parcels sized to look like somebody's skincare order, and it took a tip and fourteen months to assemble into a case. Cosmetics were 36% of all K-brand counterfeits stopped at Korean customs in 2025, the largest category in the table. Where does liability sit when the sale happens on a marketplace? The listings ran through open-marketplace seller accounts on Coupang and Naver. In that arrangement the platform is an intermediary — it hosts the listing and processes the transaction, and the seller of record is the merchant account. The consumer's contract is with that account. The brand owner's remedy is a trademark action against whoever controls it. The product regulator's remedy requires a registrant, and there is none. The result is that the party holding the most complete transaction record — listing history, shipment volumes, return rates, buyer complaints, the repeat SKUs moving out of a single Cheongju address — carries the lightest product-law exposure of anyone in the chain. Eighty-three thousand units of one merchant's counterfeit inventory is a pattern visible in platform data long before it is visible to a customs scanner or a laboratory. None of this is an argument that the platforms broke a rule. It is an observation about where the information sits relative to where the obligations sit, and the two are in different places. What does the case change for the industry? For manufacturers and contract developers, the copy target has moved down the price ladder. A formulation's commercial defensibility has rested on the assumption that mid-priced products are not worth faking. Twenty-eight cosmetics types including three mid-market Korean brands is evidence against that assumption. Formulation complexity is no longer a moat when the counterfeit contains no formulation at all. For brands and buyers, the exposure has changed direction. A brand that scaled through many channels at once now carries a counterfeit problem in its domestic market as well as its export markets, and authentication at the point of sale is brand-side work. No other party in the chain is positioned to perform it, and no other party bears the reputational loss when a consumer applies an unregulated product from Shenzhen believing it to be a Korean one. For regulators and investors, the finding is about architecture rather than effort. Korea's cosmetics regime governs entities, and it governs them competently. The parcel channel and the marketplace listing are transactions that produce no entity. Enforcement capacity added to the existing regime does not reach them, because the regime has nothing to attach to. Closing the gap means putting an obligation on a transaction rather than on a licence, which is a legislative decision and not an inspection schedule. The counterfeits did not defeat Korea's cosmetics controls. They travelled past the point where those controls stand.

On 9 September 2026 APR disclosed an absorption merger with APR Factory, a subsidiary it already owns outright. The merger ratio is 1 to 0. No shares are issued, the contract is dated 16 September and the books close on 31 December. Nothing in the filing moves capital. What moves is the boundary of the company: beauty devices fell from 43% of APR's revenue in 2024 to 18% in the first half of 2026, and APR is absorbing the device plants anyway. ⓒAPR What did APR actually file on 9 September? APR, the Korean company behind Medicube, filed to absorb APR Factory, its wholly owned production arm. The terms are unusual only in how little they do. The merger ratio is 1 to 0, no new shares are issued, and the shareholder register is unchanged. The merger contract is dated 16 September 2026 and the merger date is 31 December 2026. APR Factory operates three plants, one in Gasan, Seoul and two in Pyeongtaek, Gyeonggi Province, and has run research, product planning, manufacturing and logistics as a single chain inside the subsidiary. APR gave two reasons. The first is the standard one: organizational efficiency, cost reduction, simpler decision-making. The second is the one worth reading twice. The filing also cites upgrading production infrastructure for energy-based beauty devices and skin boosters, which are new businesses rather than the ones the plants currently serve. Consolidated financials are unaffected, because APR Factory was already consolidated. On a separate-entity basis, Bloter reported on 10 September 2026 that the 18% margin APR Factory booked on internal transactions comes out of the accounts. That is the entire financial content of the disclosure. Why absorb a subsidiary the company already owns entirely? An absorption merger dissolves one company into another; at a 1 to 0 ratio the absorbed company's shares are extinguished without compensation, because the acquirer already holds all of them. There is no price, no counterparty and no negotiation. A merger of this shape is not a transaction. It is a redrawing of where the company's edge sits. The edge mattered because APR Factory had been operating as a contract manufacturer with one customer. It became a wholly owned subsidiary in April 2023. Its revenue went from 6.8 billion won (5 million USD) in 2023 to 118.7 billion won (88 million USD) in 2025, and 97% of that came from APR itself. All currency conversions here use the 11 September 2026 close of 1,345.9 won to the dollar. So APR had built, inside its own group, a miniature of the arrangement the rest of K-beauty rents from outside: a plant that makes things, charges a margin, and answers to a brand. The merger deletes the invoice between them. APR Factory booked 97% of its 2025 revenue from a single customer: its own parent. What operating grammar does this break? Korea's Cosmetics Act registers two separate businesses. A cosmetics manufacturer makes all or part of a product. A responsible distributor manages the quality and safety of the products it handles and distributes them, including products made under contract by a manufacturer. A brand registers as the second and never as the first. That legal split is the foundation of the asset-light Korean beauty company, and it is why an indie brand with a dozen employees can ship a serum into forty countries. ODM stands for original design manufacturing, where the contract manufacturer supplies the formulation as well as the production. The Korean layer that provides it is enormous. Cosmax reported 794.9 billion won (591 million USD) of revenue in the second quarter of 2026, up 27.5%, and Kolmar reported 861.3 billion won (640 million USD), up 17.9%, with both attributing growth to indie brands entering the United States, Europe and Japan at the same time. Nothing about that layer is weakening. It is doing the best business in its history. The question is what it does not cover. APR FACTORY at Pyeongtaek, ⓒAPR Blog Is there an equivalent layer for beauty devices? Device contract manufacturers exist in Korea, but not at a comparable scale. Easytem, one of the better-known beauty device OEM and ODM firms, was founded in 2008, is based in Siheung, remains unlisted and employed 73 people as of July 2026, with 88 registered patents. Set that against a single quarter of Cosmax revenue and the asymmetry is the whole story. A cosmetics brand rents formulation, regulatory filing and capacity from a partner with billions in annual sales. A device brand rents assembly from a company with dozens of engineers. APR ran that experiment itself. Before 2023 its devices were produced outside. Its first plant opened in Gasan, Seoul in July 2023 at about 2,314 square metres with capacity of roughly 700,000 units a year and about 20 development and manufacturing staff, and the company described the reason as control of cost and inventory across the chain. The Pyeongtaek second campus followed in May 2024, with a company target of up to 8 million devices a year across 12 lines of 5,000 units each. Those capacity figures are the company's own. ⓒAPR Blog What does a Class 4 filing do to the choice? Korea grades medical devices from 1 to 4 by potential risk. Classes 1 and 2 clear through notification or certification. Classes 3 and 4 require approval from the Ministry of Food and Drug Safety, and good manufacturing practice conformity is assessed against the manufacturer and its plant rather than against a distributor. A brand cannot register itself as the responsible seller of a Class 4 device the way it registers as the responsible distributor of a cream. APR is pursuing approvals that include a Class 4 skin booster, alongside a tissue-repair biomaterial filing, and Bloter reported on 22 September 2025 that those approvals were in progress rather than granted. A skin booster is an injectable that delivers polynucleotide material into the skin; PDRN, polydeoxyribonucleotide, is the DNA-fragment raw material those products are built on. Bloter also noted that United States approval is slower because the FDA has no skin booster category. The contrast with home devices is sharp. A home beauty device sold without a medical efficacy claim is a consumer electrical product carrying KC safety and electromagnetic compatibility marks. Claim that it treats a condition and it becomes a medical device requiring approval. APR's stated direction is from home care into clinics, with radiofrequency and ultrasound energy-based devices and polynucleotide skin boosters aimed at hospital channels. That is the mechanism. A brand moving from cosmetics to clinic-grade devices does not lose access to contract manufacturing because no one offers it. It loses access because the approval and the quality system attach to whoever owns the line. ⓒAPR Blog What is the Pyeongtaek campus actually for? APR announced a third campus in Poseung-eup, Pyeongtaek on 2 September 2024: 12,859 square metres of land, 4,284 square metres of building, and production of PDRN and polynucleotide raw material of up to 125 kilograms a year, 360 tons of PDRN-based cosmetics, and a planned 20,000 prefilled syringes a day, staffed by around 20 people. Those figures come from the company's own announcement. A prefilled syringe line is not a cosmetics line item. Neither is in-house polynucleotide synthesis. Both are inputs to a regulated injectable business, and both sit inside the entity APR is now dissolving into itself. Read the three plants together and the asset being absorbed is not a factory with spare capacity for skincare. It is device assembly, biomaterial synthesis and a sterile filling plan, which is the physical footprint of a medical device company. Does the revenue mix justify any of it? Not on current numbers, which is what makes the filing interesting. APR reported second-quarter 2026 revenue of 767.5 billion won (570 million USD), up 134.2%, operating profit of 190.6 billion won (142 million USD), up 134.5%, and an operating margin of 24.8%. First-half revenue of 1.36 trillion won (1.01 billion USD) came close to the 1.527 trillion won (1.13 billion USD) booked for all of 2025. Overseas sales exceeded 90% of the total, with North America at 376.3 billion won (280 million USD), up 264.6%, and Europe at 145.1 billion won (108 million USD), up 380.3%. The beauty and cosmetics division accounted for 648.3 billion won (482 million USD) of that quarter, growing 185.5%. Devices moved the other way as a share of the business, from 43% of revenue in 2024 to 18% in the first half of 2026. So the segment paying for the plants is the segment that does not need them, and the segment the plants serve is shrinking in relative terms while its capacity is expanded. A company consolidating production for a declining share of revenue is not tidying up. It is stating where it expects the next margin pool to be, and it is not in the jar. Beauty devices were 43% of APR's revenue in 2024. In the first half of 2026 they were 18%. How is this different from the ODM expansion wave? Three contract manufacturers filed capacity expansions in the same window. Cosmecca committed 200 billion won (149 million USD) at Ochang in Cheongju, split into 64 billion won of land and buildings and 136 billion won (101 million USD) of production equipment, with construction starting in September 2026 and a first line running in 2027. Kolmar committed 173.3 billion won (129 million USD) in Sejong through 2028. Cosmax committed 60.5 billion won (45 million USD) in Pyeongtaek. This site read the Cosmecca filing as a supply-side move: an outsourcing business reclaiming margin by owning more of the capacity it had been renting out. That reading holds. A companion piece read the Cosmax and L'Oreal agreement from the other end of the same shift, where what Korea sells into the partnership is formulation rather than labour. Both describe a contract layer moving up the value chain while keeping its customers. APR's filing describes a customer leaving it. Cosmecca, Kolmar and Cosmax are adding capacity for other people's brands, which deepens the ODM model by making it cheaper and faster to stay asset-light. APR is adding capacity for exactly one brand, which exits the model for the category it cannot buy. Two of these investments sit in Pyeongtaek and point in opposite directions. Three ODM filings add capacity for other people's brands. APR's three plants add capacity for one. What does a captive line cost that a rented one does not? Fixed cost and utilization risk. Rented capacity converts production into a variable expense that scales with orders; an owned line has to be filled. APR Factory's 118.7 billion won (88 million USD) of 2025 revenue was 97% internal, which means the plants have no external order book to absorb a slow quarter. The 18% margin the subsidiary charged its parent was the internal price of that capacity, and removing it improves the parent's separate accounts without changing what the plants cost to run. The cash effect is presentational. The operating effect is that APR now carries device and biomaterial manufacturing directly on its own balance sheet, in a period when devices are falling as a share of sales. That is the trade. A cosmetics brand that rents production can walk away from a category in a quarter. A brand that owns a prefilled syringe line cannot. ⓒAPR Blog Where does this leave the model? For contract manufacturers, nothing here threatens the cosmetics franchise. Indie volume is what filled the Cosmecca, Kolmar and Cosmax filings, and that demand is growing. What the layer does not supply is device assembly and regulated biomaterial capacity at the scale brands now want. The gap APR is filling by itself reads as an unserved product line rather than a lost customer. For brands and buyers, the asset-light path holds only where a contract layer exists. Any category graded 3 or 4 puts the approval and the quality system on the maker, which means a buyer sourcing a device from a beauty brand is sourcing from a manufacturer, with the diligence that implies. The question to ask a K-beauty supplier is no longer who formulates the product. It is who holds the approval. For regulators and investors, cosmetics and medical devices are governed by separate statutes and are converging inside single companies. Valuing APR as a cosmetics brand misprices the capital going into Pyeongtaek. Reading a polynucleotide skin booster as a beauty product misreads what Class 4 means. The merger issues no shares and pays no one. It moves a factory inside a company. That is the whole disclosure, and it is enough.

Hyundai Department Store opens Khōde, a 165 square metre derma beauty shop, on the basement floor of its Pangyo store on 18 September 2026, with around 60 brands and some 250 products aimed at shoppers in their thirties and forties. Olive Young is not absent from this category. It put an Advanced Derma section into 650 of its stores within four months of launching it in March 2026. The category is not what separates them. The format is. One question used to carry Korean market validation. It now has three different answers. What opens in Pangyo on 18 September? Khōde is a standalone shop on the first basement level of Hyundai Department Store's Pangyo branch, 165 square metres, opening on 18 September 2026. Derma beauty is the industry term for skincare positioned on a clinical rationale rather than a cosmetic one, usually developed with pharmaceutical companies or dermatologists and sold on ingredient function. The assortment reflects that definition. Hyundai has said the shop carries around 60 brands and some 250 products, drawing on pharmaceutical lines including Daewoong's EzDue, Dongkuk's Madeca Pharmacia and Adesee, alongside dermatologist-developed labels such as Foredem and Judak, with hair and body ranges included. A second location is planned at The Hyundai Seoul in the first half of 2027, with further sites across department stores and outlets after that. Those figures are as announced in August, ahead of opening. Hyundai describes the shop as the first dedicated derma beauty specialty store in Korean retail. That is the company's framing of its own launch, and derma products have been on other retailers' shelves for some time. What is new is the container, not the contents. Khōde, ⓒHyundai Department Store Is the category actually new? No, and the numbers make that plain. Olive Young launched its Advanced Derma category in March 2026 and had it running in 650 stores four months later, roughly half its network, developed with domestic pharmaceutical partners. June sales in the category were reported up more than 260% on April. Foreign customers accounted for about 70% of it. So the incumbent did not miss derma. It moved first, moved fast, and moved at a scale no department store can match on store count. Anyone reading the Khōde opening as a chain retailer being caught out has the sequence backwards. The interesting question is why two retailers looking at the same demand built two different things. What did the department stores build instead? Not a category inside existing stores. A separate format with its own footprint, its own assortment logic and its own location. Three of them are now running inside one quarter. Hyundai's Khōde opens on 18 September. Shinsegae operates Chicor in Myeongdong and Hongdae. Lotte opened The Cast at its Cheongnyangni store in April 2026. Each occupies a different position, and none of the three is trying to be a smaller Olive Young. A category and a format differ in what they can vary. A category has to work the same way in every store that carries it, because that is what makes it deployable across a network. A format is built once, for one building, and can be tuned to whatever that building's traffic is. What position does Shinsegae hold? A tourist business, and the share is not marginal. As of April 2026, foreign customers accounted for 90.2% of sales at Chicor Myeongdong and 91% at Chicor Hongdae. Hongdae sales doubled within about four months of opening, and skincare sales there rose more than two and a half times between January and April. Those are not Korean stores with tourist upside. At nine in ten, the Korean shopper is the marginal customer and the visitor is the business. Assortment, language, staffing and even opening hours follow from that, and none of those choices would survive being standardised across a national network where most branches serve a neighbourhood. Olive Young put derma into 650 stores in four months. Hyundai put it into one store of 165 square metres. What position does Lotte hold? A studio. The Cast opened at Cheongnyangni in April 2026 built around influencer livestreaming with online purchase attached, and went from 30 brands to 60 within two months. The retail floor is the set. What is being sold from it reaches an audience that is not in the building, which makes the store's catchment a function of the broadcast rather than the district. That is a different business from either a derma shop or a tourist shop, and it is the clearest case of the three that a physical format is now being designed around a specific mechanism rather than around footfall. Why does Olive Young not simply do all three? Nothing prevents it, and it is already doing a version of one of them. Its foreign customer transactions passed one trillion won by August 2026, three months earlier than in 2025, and its Advanced Derma displays are concentrated in tourism districts and high-demand beauty areas. At its Seongsu consultation service, more than 80% of users are international visitors. The constraint is arithmetic, not capability. Olive Young operated 1,369 stores at the end of March 2026. A network that size earns its margin from uniformity: one planogram, one training package, one assortment decision replicated everywhere. Every location-specific format is an exception to that, and exceptions are what a standardised chain is built to avoid. A department store starts from the opposite place. It already runs every floor of every building differently, with different tenants, different margins and different staffing. Adding one more differently-run 165 square metre room costs it very little organisationally. That asymmetry, rather than any gap in ambition, is what separates a category from a format here. What does this do to the signal a buyer reads? It thins it. Until now, one sentence carried Korean market validation for a foreign buyer: the brand is in Olive Young. That sentence did a great deal of work, and it was earned — more than 116 brands there generate over 10 billion won a year and six exceed 100 billion. The shelf is now separating into positions that mean different things. Discovery sits at the bottom of the price ladder, where Daiso has gone from seven beauty brands in 2022 to more than 170, with estimated cosmetics purchases up 39.6% year on year. Verification sits in the derma formats, where the claim is clinical and the assortment is small. Tourism sits in stores where nine in ten customers are foreign. A brand that is in all three is telling you nothing. A brand that is in exactly one is telling you what it is. The question a buyer asks shifts from whether a brand has Korean distribution to which shelf accepted it. Foreign customers were 90.2% of Chicor Myeongdong's sales in April 2026. For Olive Young's derma category they were about 70%. Which brands does this favour, and which does it strand? It favours brands with a rationale that survives being explained. A shop of 60 brands is an editorial position rather than a distribution channel, and the entry ticket is a clinical story a staff member can repeat: a pharmaceutical parent, a dermatologist developer, an ingredient with a mechanism. Khōde's assortment is built almost entirely from brands that have one. It strands brands whose case was velocity. A product that sells because it is moving fast needs a wide shelf to move on, and 165 square metres is a much narrower door than 1,369 stores. The same brand that a chain buyer takes because the data is trending is the brand a 60-slot editor has no room for. There is also a cost few brands have priced. A format that sells on consultation needs someone on the floor who can hold the conversation, and that training is paid for by whoever wants the placement. Hyundai Department Store's Pangyo branch Where does this leave the channel? For brands and manufacturers, distribution strategy stops being a single target. Getting into Olive Young and getting into a 60-brand derma shop are different sales, with different evidence, different margins and different volumes, and a brand built to win one is not automatically built to win the other. The ingredient rationale that a derma format requires has to exist before the pitch, which means it is a development decision rather than a sales one. For buyers, the useful question changes. Asking whether a Korean brand has domestic distribution now returns an answer that covers everything from a 5,000 won aisle to a 90%-foreign tourist store. Asking which format carries it, and what that format's assortment logic is, returns something that actually describes the brand. For retailers and investors, the split is the point rather than the winner. Olive Young's scale advantage is undiminished and its derma numbers are the strongest in the market. What has changed is that scale no longer covers every position on the shelf, and the positions it does not cover are now occupied by operators whose cost structure suits them. Three formats opened in one quarter. None of them is competing with Olive Young on its own terms, which is the only reason any of them is interesting.

Korea convened cosmetics regulators from twelve countries in Seoul, founded a standing council, took its inaugural chair, secured its permanent secretariat, and booked the second meeting for Korea in 2027. Read in isolation, it is a routine multilateral launch. Read alongside the safety-assessment regime Korea imposes on its own industry from 2028, its purpose becomes considerably more legible—and the implications reach further into the ODM relationship than the announcement suggests. 1. What Was Established The Global Cosmetics Regulatory Authority Summit (GCORAS) was founded at The Plaza Hotel Seoul over three days beginning 7 September 2026, convened by the Ministry of Food and Drug Safety (MFDS). Three outcomes were confirmed after the closed plenary: Korea was elected inaugural chair. The permanent secretariat will be established in Korea. The second summit, in 2027, will also be held in Korea. Delegates adopted a declaration and agreed on a framework for expanding cooperation through working groups on regulatory information and scientific and technical developments. The participants are described as twelve countries together with industry associations from Asia and Europe, totaling fifteen organizations. Korean coverage names Vietnam, Thailand, Indonesia, Malaysia, and the Philippines among the ASEAN participants, the UAE in the Middle East, and Brazil and Mexico in Latin America. The distinction between countries and associations matters, and early reporting blurred it. Fifteen is not fifteen regulators. It is twelve national regulatory authorities plus trade associations—the European and Australian cosmetics associations took part in the industry consultation sessions, and Australia and New Zealand appeared on the day-one forum program as presenters rather than as members. The launch was reported in Korea and barely registered outside it. What none of the coverage does—Korean or English—is set the summit beside the obligation Korea places on its own industry from 2028. The Global Cosmetics Regulatory Authority Summit (GCORAS) 2. Background: Three Convergent Changes 2.1 The Export Base Changed Composition, Not Only Scale Korea exported $11.42 billion of cosmetics in 2025, ranking second worldwide, up from third the previous year. France remains first at $24.28 billion and the United States third at $10.75 billion. The 2015 figure was $2.5 billion, making the decade's growth roughly fourfold. For the first time, Korea's largest single destination was the United States, at $2.18 billion, ahead of China at $2.02 billion. The scale figures are the ones customarily reported. The compositional change matters more, and MFDS identifies it directly: demand has become hyper-personalized, distribution has shifted to high-mix, low-volume, and cross-border commerce is increasingly influencer-led. In commercial terms, Korea's export engine is no longer a small number of large houses moving large volumes into a single market. It is several thousand small brands, most manufacturing through ODMs, selling modest volumes into many markets simultaneously, frequently through channels that postdate the statutes governing them. That structure is commercially formidable and regulatorily fragile. A large firm absorbs twelve registration regimes as a cost of doing business. A twenty-person brand cannot. Korea's growth is now concentrated in precisely the firms least able to carry compliance load. The Ministry of Food and Drug Safety (MFDS) 2.2 Technical Barriers Have Replaced Tariffs MFDS is explicit on the second change: technical barriers to trade are rising as major markets tighten safety, environmental, and quality requirements, with mandatory safety assessment, GMP, and halal certification named specifically. None of these is a tariff. Each functions as one, and each falls disproportionately on small exporters, because the cost of a compliance dossier scales weakly with volume. 2.3 Korea Has Joined the Countries Raising Them Korea's amended Cosmetics Act was promulgated on 30 December 2025, establishing mandatory cosmetic safety assessments. The law requires a documented demonstration that a product is safe under normal or reasonably foreseeable conditions of use, prepared by a qualified assessor and retained by the responsible seller. The statutory phasing begins in 2028 for firms above KRW 1 billion in annual production or import value alongside all new product launches, expanding annually until covering all companies and products by 2031. Dossiers must include quantitative and qualitative composition data, impurity thresholds, preservative efficacy testing, and packaging compatibility reviews. Yu-Kyoung Oh, the Minister of the Ministry of Food and Drug Safety 3. The Case for Reading GCORAS as Risk Management From 2028, Korean brands will pay for safety assessment irrespective of whether any foreign authority recognizes it. That cost is sunk domestically. Its value abroad turns on a single question: whether Vietnam, Indonesia, Malaysia, the UAE, Brazil, and Mexico accept the resulting dossier, or require a second one. If accepted: The 2028 mandate becomes an export asset—one dossier serving many markets, and a compliance burden converted into an advantage, since Korean firms will have paid it and competitors in other origin countries will not have. If rejected: The mandate is overhead layered atop every existing foreign requirement, borne by the smallest firms in the export base. The summit's agenda is consistent with the first objective. Its stated items—safety assessment, GMP, halal certification, digital distribution, cross-border commerce—are not a generic list. They are the same barriers MFDS identifies as rising, with safety assessment at the head of both. The day-one forum program points the same way: alongside sessions on EU regulatory change and the Australian and New Zealand frameworks, it carried a session on the use of artificial intelligence in cosmetic safety assessment—which is to say, on how to make the 2028 dossier cheap enough to produce at the scale Korea's indie tier would require. So does the timing. Detailed rulemaking for the 2028 phase-in is underway now. A working group convened in 2026 has approximately the runway required to matter by then; one convened in 2029 does not. Intent cannot be established from a press release. But the shape of the initiative fits a specific purpose: Korea appears to be pre-building mutual recognition for a compliance regime it is about to impose on itself. The domestic industry reads it the same way. Welcoming the outcome, the Korea Cosmetic Association—chaired by Amorepacific—said it expected GCORAS to develop beyond information exchange into substantive regulatory cooperation, and committed to ensuring that the difficulties Korean firms encounter reach foreign authorities in concrete form and translate into eased regulatory burden. That is not ceremonial language. It is an industry telling its government what the body is for. Suh Kyung-bae, the chairman of the Korea Cosmetic Association 4. Why a Second Forum: GCORAS and ICCR Compared International cooperation on cosmetics regulation is not new to Korea—MFDS already sits on the steering committee of the International Cooperation on Cosmetics Regulation (ICCR), established in 2007. The emergence of GCORAS represents a shift from participating in standard-setting to leading a regulatory body tailored to Korea's primary export destinations: Feature ICCR (Est. 2007) GCORAS (Est. 2026) Primary Scope Convergence among mature Western & traditional cosmetic powers Managing regulatory friction across key emerging K-Beauty export markets Member Roster US FDA, EU, Japan MHLW, UK, Canada, Brazil, etc. South Korea, Vietnam, Thailand, Indonesia, Malaysia, Philippines, UAE, Mexico, Brazil, etc. Korea's Standing 1 of 9 committee members Inaugural Chair, Permanent Secretariat, & Recurring Host Strategic Dynamic Where Korea takes rules Where Korea makes rules This distinction goes beyond a geographical split. ICCR governs the mature markets whose rules Korea must adapt to; GCORAS addresses the emerging markets where Korean exports encounter immediate technical friction. By securing the chair, housing the permanent secretariat, and hosting the second summit, Korea holds all three structural levers to shape the agenda for its key export markets—a dedicated platform that did not previously exist. 5. Implications by Segment Korean Brand Operators: Treat the KRW 1 billion threshold—not 2031—as the operational deadline. Qualifying new launches within the phase-in window triggers compliance immediately. Because certified safety assessors represent a finite talent pool, contracting compliance capacity early prevents severe cost spikes during the final implementation rush. Indie Founders: Safety assessment acts as a fixed compliance cost that inherently favors scale. To protect margins on smaller production runs, brands will need to rely heavily on ODM regulatory infrastructure or leverage emerging AI safety-assessment tools to automate dossier generation and lower fixed unit costs. ODMs and Contract Manufacturers: Managing safety data alongside formulation IP transforms regulatory compliance into a critical service line, creating permanent, high-barrier client lock-in that extends far beyond contract manufacturing. Overseas Buyers: Audit Korean supplier portfolios for 2028 dossier readiness today. Suppliers with established safety-assessment pipelines offer a faster, lower-friction expansion route into ASEAN, the Middle East, and Latin America. Exporters to ASEAN and the Gulf: Focus on the technical working groups established at the summit. The multi-national consultation formats introduced in Seoul offer a direct template for submitting industry inquiries and seeking regulatory clearance through national trade associations. 6. Failure Modes Divergence Rather Than Convergence: A second bloc can entrench two standards as readily as it can reconcile them. Should GCORAS settle on requirements meaningfully different from EU or ICCR practice, Korean exporters would serve two regimes rather than one, doubling the compliance cost instead of halving it. Korea's dual membership hedges this but does not resolve it. Convening Power Is Not Authority: What the summit produced are containers: a chair, a secretariat, a declaration, working groups. None shortens a registration timeline. The base rate for international bodies that produce a declaration and thereafter an annual meeting is not low. Asymmetry, Now on the Record: Korea convened the body, holds the chair, houses the secretariat, and hosts the next meeting. That concentration is efficient in year one and a liability by year three. The other eleven members will expect reciprocity—regulatory science capacity, assessor training, inspection recognition, technical assistance—and the first real test of GCORAS will be whether the chair rotates and the agenda accommodates a priority Korea did not set. What Korea offers is the price of the arrangement, and it will appear in MFDS budget lines before it appears in declarations. 7. A Note on the 46 Percent Figure MFDS states that participating countries account for approximately 46 percent of the global cosmetics export market and provides no methodology. Every subsequent report repeats the figure without one. As exporters, these countries are not large. Korea itself accounts for $11.42 billion and France alone for $24.28 billion; Vietnam, Thailand, Indonesia, Malaysia, the Philippines, the UAE, and Mexico do not close that gap. The figure may refer to destination markets rather than countries of origin, or may depend on participants not yet named. It cannot be reconstructed from public trade data. The point is practical rather than pedantic: the number is doing rhetorical work, and any executive who repeats it should expect to be asked for its basis. Global Cosmetics Regulatory Authority Summit (GCORAS) 8. Assessment There are two routes from taking rules to making them: promotion within an existing body, or establishment of a new one. Korea's beauty industry has a long record of the second. It did not secure shelf space at incumbent Western retailers and scale from there; it built Olive Young and is now exporting the format. Its manufacturers did not wait for invitations into global brand development; they built ODM capability deep enough that the invitations followed. GCORAS applies that approach to regulation, and the timing is the most telling element. The body was not established in 2029, after the mandate had taken effect and exporters had begun reporting duplicated dossiers. It was established two years ahead, while the rulemaking is still being drafted and the terms remain movable—and Korea secured the chair, the secretariat, and the next venue in the same week it opened the doors. Whether it succeeds is an open question. Whether it was deliberate is not.

The temporary brightening of the skin can occur simply from thoroughly rinsing your face with cold water in the morning—it is a physiological illusion. Blending a few basic ingredients like glycerin and niacinamide almost guarantees that clinical testing devices will spit out passing grades as if on cue. This exposes the unvarnished reality behind the glowing claims—such as "140% Moisture Retention Improvement" or "Pores Reduced in 4 Weeks"—that adorn product packaging. While consumers imagine lab-coated researchers conducting rigorous scientific validation, the figures dominating the market resemble financial products meticulously engineered by a marketing cartel rather than scientific truths. Tae-il Kwak, CEO of the regulatory cosmetics SaaS platform CDRI, addressed a room of beauty brand managers. Rather than offering a sugary formula for success, he unveiled the bizarre cost structure of the clinical trial market—a secret the industry had maintained under strict silence. The true nature of the scientific data consumers blindly trust had long been K-Beauty's largest, most quietly acknowledged open secret. In a market ruled by metrics, truth is continually re-engineered to meet capital demands. The Magic of "49% Hydration" Begins in Strategy, Not the Lab The raw cost of a standard hydration test—factoring in subject compensation, equipment usage, labor, and report drafting—amounts to barely a thousand dollars. Yet, after passing through layers of markup, this modest internal cost balloons into tens of thousands when billed to brand owners. This extreme profit margin, unthinkable in traditional manufacturing, is made possible because modern clinical testing equipment has become remarkably sophisticated. Where legacy devices measured a single metric, today’s machinery captures pore size, elasticity, and cleansing efficacy simultaneously in a single session. For testing laboratories, this yields additional data at virtually zero incremental cost. Instead of bundling it, labs issue separate invoices for each parameter to maximize margins. As philosopher Jean Baudrillard observed regarding consumer society, "We do not consume the object itself; we consume the sign." Clinical trials in K-Beauty have largely ceased to be rigorous validations of efficacy; they have devolved into a commercial circus where brands buy numeric symbols to display on store shelves. Platform data from CDRI—which serves over 1,700 client companies—reveals that fast-growing, top-selling brands have already recognized this illusion. They forgo spending tens of thousands on high-end device evaluations. Instead, they secure cost-effective claims like "90% felt a soothing effect" through simple user surveys, reallocating the saved capital into influencer seeding and product design. Overpaying out of an obsession with device-measured figures is a mistake primarily made by inexperienced brands. The Traps of Annual Retainers and Grey Market Temptations The clinical trial industry maintains impressive operating profit margins of 30% to 40%. Underlying these margins is the lucrative trap of annual retainer contracts. Enterprise corporations and growing brands sign these agreements intending to save money, yet doing so grants laboratories exclusive leverage and strips the brands of bargaining power. Projects that should cost $30,000 routinely balloon into $100,000 under the banner of annual retainers. Compounding the issue is a grey market operating on the fringes of compliance and ethics. "Subject recycling" is a widely known industry practice. Professional test subjects move between facilities—measuring hydration at Lab A in the morning, testing elasticity at Lab B by noon, and visiting Lab C in the evening. Exploiting legal loopholes, certain testing facilities drastically undercut labor costs and lure brands with dumped pricing. The adage "you get what you pay for" applies directly here. Below-market clinical reports often rely on compromised subject data and the temptation to manipulate numbers to guarantee results. Some labs continuously tweak dataset parameters until achieving the client's desired outcome. Clinical testing, which ought to guarantee objective scientific validity, risks turning into a tailored performance dictated by commercial demands. The Global Registration Trap: A $3 Million Risk Domestically, a reliance on cheap or lax clinical practices becomes a catastrophic liability when entering major overseas markets like the United States and Europe. A common oversight among K-Beauty brands is assuming foreign regulatory frameworks mirror local ones. While domestic authorities operate under a pre-market approval system—granting permission once guidelines are met—international frameworks like MoCRA in the US and CPNP in Europe rely on post-market compliance. Companies freely register products, but bear full legal accountability if issues arise. Lower entry barriers carry severe downside risks if non-compliance is uncovered later. A domestic brand scaling rapidly on platforms like Amazon faced litigation in the US due to inadequate efficacy substantiation data, with initial claims starting at roughly $3 million. While domestic administrative penalties may only involve temporary sales suspensions or modest fines, Western punitive damages and class-action lawsuits threaten a brand's core viability. Navigating global markets with compromised clinical reports compiled solely for local marketing is a severe operational hazard. For export-oriented businesses, clinical trials are mandatory—not as promotional tools, but as critical legal risk mitigation. This necessity has driven the adoption of SaaS platforms that cross-validate thousands of clinical reports via AI, ensuring multi-ethnic data validity and statistical integrity. The cosmetics sector is shifting from emotional branding toward strict data integrity. Escaping Numeric Obsession to Reclaim Core Brand Values The turbulence surrounding cosmetics clinical trials reflects brands trapping themselves in an artificial game of metrics. Consumers deciding on products care little whether a label claims a 15% or 25% improvement. They focus on intuitive appeal, personal fit, and underlying brand trust. A marginal percentage increase no longer drives purchasing decisions, making exorbitant spending on unnecessary clinical testing an inefficient use of capital. The foundation of the cosmetics industry rests on honest formulations using quality ingredients, coupled with marketing that resonates with consumers. Domestic clinical strategies should prioritize cost-effective survey-based evaluations to conserve capital, while international testing must be structured as robust compliance documentation against legal liability. Brands must avoid squandering product development and marketing budgets on inflated laboratory pitches. K-Beauty must move past superficial metrics and realign its strategies with global market realities.

Between 2 and 7 September 2026, MBK Partners put roughly 470 billion won ($349 million) into two Korean beauty assets. One is a control buyout of Skin Idea and Life&Bio at about 300 billion won ($223 million), near eight times combined EBITDA. The other is 172 billion won ($128 million) for 40% of AXIS-Y's parent at a 430 billion won ($320 million) valuation, founder still in control. Korea's largest buyout firm bought the cash and the option at once, and has not decided which one K-beauty is. One deal bought 34.4 billion won ($26 million) of existing EBITDA; the other bought a 430 billion won ($320 million) valuation on a brand founded in 2019. What did MBK Partners sign in the first week of September? The first transaction became public on 2 September. MBK Partners' Special Situations division — the arm that ordinarily writes mezzanine and minority cheques rather than buying companies outright — agreed to acquire 67% of Skin Idea and 81% of Life&Bio from Morgan Stanley Private Equity for approximately 300 billion won ($223 million; dollar figures throughout convert at 1,345.9 won per dollar, the 11 September 2026 close). The share purchase agreement was signed in August. Skin Idea operates the derma-aesthetic brands Medifill and Derma Maison, and reported revenue of 104.5 billion won ($78 million) and EBITDA of 27.5 billion won ($20 million). Life&Bio, a health-supplement business that has itself acquired the food company FoodCare, reported consolidated revenue of 44.2 billion won ($33 million) and EBITDA of 6.9 billion won ($5.1 million). Existing management stays in place at both. EBITDA — earnings before interest, taxes, depreciation and amortisation — is the standard proxy for the cash a business throws off before financing and accounting choices. Combined, the two companies produce 34.4 billion won ($26 million) of it. Against a 300 billion won ($223 million) price, that is 8.7 times, and reports describe the pricing as roughly eight times. The second transaction was announced on 7 September. MBK agreed to take 40% of Asia Master Trade, the company behind the brand AXIS-Y, for approximately 172 billion won ($128 million) at a valuation of about 430 billion won ($320 million). The founder retains 60% and operational control. AXIS-Y was founded in 2019, draws more than 90% of revenue from outside Korea, sells in roughly 100 countries, and entered Olive Young — Korea's dominant health-and-beauty chain — only in 2025. By the company's own announcement, its Dark Spot Correcting Glow Serum has sold more than 20 million units cumulatively. MBK is its first institutional investment partner. Why are these two deals structurally opposite? A control buyout and a minority growth investment are not two sizes of the same thing. They answer different questions and they pay for different risks. In a control buyout the acquirer owns the outcome. It sets the capital structure, replaces or keeps management, decides when and how to exit, and underwrites the price against cash the business already generates. The discipline shows up in the multiple: eight times EBITDA on a domestic derma and wellness platform is a price that works if the earnings hold, and it does not require the business to become something it is not. In a minority growth investment the acquirer owns a claim on someone else's execution. MBK does not control AXIS-Y, cannot direct it, and is paid only if the founder keeps compounding the brand. The 430 billion won ($320 million) valuation is not supported by a disclosed EBITDA figure at all. It is supported by a market position — roughly 100 countries, more than 90% of revenue earned abroad — and by a judgment about how long that position lasts. Same firm, same week, same sector, opposite risk. One deal says K-beauty is an earnings stream to be bought at a defensible multiple. The other says it is an equity story with a long runway. Those are not complementary theses. They are alternatives, and holding both is a statement that the question is open. A vibrant display of Axis-Y skincare products, featuring toners, serums, and sunscreens, ⓒAxis-Y What does an eight-times price say about the asset being bought? It says the buyer treated the business as a going concern rather than a growth narrative. Eight times EBITDA is the kind of number that clears an investment committee on downside arithmetic: the earnings cover the price within a decade of flat performance, and any growth is upside rather than the basis of the case. MBK's stated rationale points the same direction. The firm cited structural growth in domestic wellness — an ageing population, rising incomes, and increasing spend on prevention rather than treatment. That is a demographic argument about Korean consumers at home, not an export argument. Skin Idea and Life&Bio are being bought for what Koreans will keep spending on inside Korea. Note what this pricing implies about the seller's position too. A disciplined multiple on a business with 34.4 billion won ($26 million) of EBITDA is a transaction that both sides can defend. Nobody in it is paying for a story. Medipeel collagen skincare products, ⓒMedipeel What is MBK buying when it pays 430 billion won for a brand founded in 2019? Distribution reach that took seven years to build and would take longer to replicate. AXIS-Y sells in roughly 100 countries with more than 90% of revenue earned outside Korea, which means the brand has already solved the problem most Korean beauty companies are still working on: demand that does not depend on one market, one retailer, or one platform algorithm. What the valuation does not rest on is a disclosed earnings base. No revenue or EBITDA figure for Asia Master Trade appears in the announcement, and the 20-million-unit figure for its lead serum comes from the company itself rather than an audited disclosure. An investor paying 430 billion won ($320 million) on that information set is pricing the brand's position, not its current profit. That is a defensible thing to pay for. It is not what the other deal paid for, and it also explains the structure. Leaving the founder with 60% and control is how a financial investor buys exposure to brand momentum without taking responsibility for producing it. Why does a brand with 90% overseas revenue reach Olive Young last? Because the standard Korean sequence has been inverted. The conventional path runs domestic first: launch into Olive Young, accumulate sell-through data, use that record to convince foreign buyers and distributors, then export. Domestic validation functions as the credential. AXIS-Y ran the sequence backwards, building overseas demand from 2019 and entering Olive Young only in 2025. The contract-manufacturing base is what makes that possible — Korea's ODM tier lets a small team develop, formulate and ship a competitive product without owning a factory or holding domestic shelf space. What had not happened until now is institutional capital putting a 430 billion won ($320 million) valuation on a company that skipped the credential entirely. That is the structural content of the AXIS-Y deal, and it travels beyond this one brand. Domestic retail performance has functioned as the entry ticket to serious valuation conversations in Korean beauty. One deal does not end that convention. It does establish a reference point for founders who never had the ticket. Morgan Stanley PE entered Life&Bio in 2021 and Skin Idea in 2024, and left both in 2026 with Korean cosmetics exports near a record. Who is selling, and why does that matter more than who is buying? The buyer generated the headlines. The seller carries the information. Morgan Stanley Private Equity acquired 81% of Life&Bio in 2021 for approximately 80 billion won ($59 million) and 67% of Skin Idea in 2024 at a valuation of about 150 billion won ($111 million). With this sale, its Korean buyout portfolio is empty. A global fund is stepping out of Korean beauty ownership at a point when Korean cosmetics exports are at record levels, and a Korean fund is stepping in. That is a rotation of ownership, not a verdict on the sector: both sides looked at the same assets and the same cycle and reached opposite conclusions about what to do next. One of them is wrong, and which one will be visible in the exit multiple three to five years from now rather than in any statement made currently. For anyone selling into or sourcing from these companies, the practical consequence is narrower and more immediate. Ownership has moved from a foreign fund with a global mandate to a domestic fund with a Korean wellness thesis. Capital allocation, category priorities and partner selection get decided in Seoul now. A collection of Medipeel skincare products, ⓒMedipeel What can and cannot be concluded about the seller's return? Less than the numbers invite. The entry figures and the exit figure are reported on different bases: 80 billion won ($59 million) as the price for a stake in 2021, about 150 billion won ($111 million) as a company valuation in 2024, and about 300 billion won ($223 million) as the combined price for controlling stakes in both businesses in 2026. Those three numbers do not subtract into a return. No outlet reports a realised return, an IRR or a money multiple for Morgan Stanley PE on either asset, and the disclosed information does not permit one to be calculated — holding periods differ, the stakes differ, intervening capital flows are not disclosed, and Life&Bio acquired FoodCare during the holding period, which changes the business that is being sold from the one that was bought. The defensible statement is the plain one: a fund that entered in 2021 and 2024 exited in 2026, in a single package, to a domestic buyer, at a disclosed price of about 300 billion won ($223 million). Everything past that is arithmetic performed on incompatible figures. Axis-Y skincare products, ⓒAxis-Y What does a portfolio holding both bets say about K-beauty as an asset class? Three readings are available, and the transactions support all three. The first: K-beauty has matured into two separable asset types, and a large fund is correct to own one of each — domestic wellness platforms priced on earnings, and born-global brands priced on reach. On this reading the five-day pairing is portfolio construction, not indecision. The second: the pairing is a hedge, and hedges are what investors build when conviction is thin. A fund that knew whether K-beauty's durable value sits in manufacturing-backed brands or in domestic consumption would concentrate rather than split 470 billion won ($349 million) across opposite structures. The third, and the one the numbers support most directly: the difference between the two deals is not the sector, it is what each seller would accept. A global fund exiting its last Korean assets sold control at eight times earnings. A founder with 90% of revenue offshore sold 40% and kept the keys. The structure followed the seller's position, not the buyer's thesis. Korean beauty assets are now priced two ways in the same week by the same firm. The earnings-based price is the one that can be checked. The other one is a claim about how long a brand's reach lasts, and that claim gets settled by the next buyer, not by this one.

On 9 September 2026 Cosmecca Korea filed a new-facility investment disclosure with the Korea Exchange: 136.0 billion won(approximately $101 million USD), equal to 40.45% of shareholders' equity, running from that day to 31 December 2030. The stated purpose was a single clause — expanding production capacity in response to increased cosmetics demand. That clause is the least interesting thing in the filing. An ODM adding capacity during the largest export boom in the industry's history is not news. The reason to read this particular disclosure is that Cosmecca is not primarily buying capacity. It is buying back a margin it has been paying to someone else. ⓒCosmecca Korea What is the 200 billion won ($148.6 million USD) actually made of? The figure quoted in the Korean press is 200 billion won ($148.6 million USD), and it is a sum of two decisions taken three months apart. In June, Cosmecca agreed to acquire an existing Ochang plant from Hansol Technics for 64.0 billion won ($47.5 million USD). In September, the board approved a further 136.0 billion won ($101.0 million USD) for new construction and equipment on the same site in the Ochang Science Industrial Complex in Heungdeok-gu, Cheongju. The site runs to 50,174.3 square metres (540,072 sq. ft.) with 58,862.83 square metres (633,595 sq. ft.) of floor area. Groundbreaking is this month, first-phase operation is scheduled for 2027, and equipment installation continues to 2030. The province and the city put the associated hiring at roughly 500 people. The phasing matters. This is not 200 billion won ($148.6 million USD) leaving the balance sheet in one quarter. It is a four-year commitment with an option to slow down, which is the only reason the leverage below is survivable. Why does an ODM with record orders need to buy a factory? Cosmecca's 2025 results, disclosed in February, were good: consolidated revenue of 640.6 billion won ($475.9 million USD) (up 22.2%), operating profit of 83.4 billion won ($62.0 million USD) (up 38.1%), net income of 57.5 billion won ($42.7 million USD) (up 7.1%). The first half of 2026 was better — revenue up 46.8%, operating profit up 52.8%, net income up roughly 99%. Second-quarter revenue from the Korean operation alone reached 178.8 billion won ($132.8 million USD), up 62.6% and a company record. Underneath that, a different line was moving faster than any of them. Outsourced processing costs — what Cosmecca pays third-party manufacturers to make product it has sold but cannot produce itself — rose from approximately 46.6 billion won ($34.6 million USD) in 2024 to 69.0 billion won ($51.3 million USD) in 2025. That is a 48% increase against revenue growth of 22.2%. Subcontracting cost grew at more than twice the rate of the business it was supporting. A hydrogel line that started the year with four production lines in January was already sold out on an order basis by July. The company was, in the most literal sense, renting the upside. ⓒCosmecca Korea What does the outsourcing line tell you that the revenue line hides? It tells you where the constraint in Korean beauty has moved. For most of the last decade, the binding constraint on a Korean ODM was demand: winning the brand, holding the account, surviving the churn when an indie label collapsed. Capacity was the easy part, and utilisation was the number that worried management. That has inverted. Order books at the top of the ODM tier are now longer than the lines available to fill them, and the overflow goes to subcontractors who price it at a level that suits them. The result is a business that looks healthy at the operating line and leaks at the gross line. Operating margin can improve on scale and administrative discipline while gross margin compresses, because every incremental unit made outside carries a processing fee that an internal line would not. This is the part worth generalising beyond one company. When a category is capacity-constrained, revenue growth stops being evidence of value creation. Some meaningful share of a Korean ODM's 2025 boom was booked as revenue by the ODM and captured as margin by its subcontractors. The Ochang investment is Cosmecca deciding that share is now large enough to buy out. There is a second cost to subcontracting that does not appear on any line of the income statement. An ODM's defensible asset is process knowledge — what a formula does on a filling line at volume, which viscosity ranges jam, how a texture behaves in the third week of a run. Product made outside teaches that lesson to someone else's engineers. A company that outsources 69.0 billion won ($51.3 million USD) of production in a single year is paying a fee and donating a curriculum, and the second is harder to reverse than the first. What is Cosmecca buying with the AI framing? The company's own description of the project leans heavily on what it calls AX — an AI-based transformation of the production process, with 2026 named as its inaugural year. The provincial and municipal announcements repeat the language. It is worth being clear about what has and has not been disclosed here. There is a site area, a floor area, a headcount, a phasing schedule and a total figure. There is no throughput target, no unit-cost target, no stated reduction in changeover time, and no description of which processes the automation actually touches. "AI-based intelligent manufacturing" is at this stage a description of intent, not a specification. That is not a reason to dismiss it. Cosmetics ODM work is unusually well suited to automation gains, because the economics are dominated by short runs and frequent changeovers rather than by long-run throughput — the indie client base that drove Cosmecca's growth orders in small batches and changes formulas often. If the Ochang line genuinely reduces changeover cost, it addresses the exact reason small orders were uneconomic to keep in-house and got pushed to subcontractors in the first place. But that is a claim the company has not yet quantified, and readers should not price it until it does. What is Cosmecca borrowing to do it? he financing is where the confidence shows, and where the risk sits. Borrowings reached 225.8 billion won ($167.8 million USD) at the end of June 2026, up 36%. The debt-to-equity ratio moved from 87.9% to 119.6% over the same period. Consolidated shareholders' equity stood at 335.9 billion won ($249.6 million USD) at the end of 2025; the filing's 40.45% ratio implies a slightly different equity base, almost certainly the separate-basis figure, but the order of magnitude is the point. Cosmecca has committed something close to two-fifths of its equity to one site. For a company with 640.6 billion won ($475.9 million USD) of annual revenue and 83.4 billion won ($62.0 million USD) of operating profit, that is a substantial but not reckless position — provided two things hold. The first phase has to reach useful utilisation reasonably soon after it opens in 2027. And the export cycle that produced a 62.6% domestic revenue quarter has to still be running when it does. Neither is guaranteed. Korean cosmetics exports have now posted ten consecutive months of year-on-year growth, and the August rate of 52.1% was the highest in thirty-one months. Committing capital at the point of maximum visible demand is exactly when capacity decisions have historically gone wrong in this industry, and every ODM management team knows it. Cosmecca is making the bet anyway, with a phased drawdown as the hedge. ⓒCosmecca Korea Is this the same bet Cosmax and Kolmar are making? Not at the same weight, and that is the distinguishing feature. Cosmax committed roughly 60.5 billion won ($44.9 million USD) to a further expansion of its Pyeongtaek plant in May. Both Cosmax and Kolmar grew first-half revenue in the low-to-mid twenties percent — Cosmax around 21.9%, Kolmar around 24.9% — against Cosmecca's 46.8%. Cosmecca is the smallest of the three by a wide margin and is making the largest single capacity commitment relative to its own balance sheet. The asymmetry is the story. The larger two are adding lines at the edges of sites they already run, in increments a fraction the size of their equity base. Cosmecca is buying a plant, building a second one beside it, and taking its debt-to-equity ratio past 119% to do both. That is not a difference of opinion about the market. It is a difference in what each company thinks it is competing for: Cosmax and Kolmar are protecting share of a mature account base, while Cosmecca is trying to change weight class before the window closes. Read one way, that is a challenger correctly seizing a window while the incumbents optimise. Read another, it is the company with the least cushion taking the most cyclical risk. The relevant history is that Cosmecca's growth has been driven disproportionately by indie and mid-sized clients — the cohort that scales fastest and disappears fastest. Internalising production for a customer base with that churn profile is a different proposition from internalising production for L'Oréal. How should an operator read this? The margin reading. This is a straightforward buy-versus-rent calculation with a visible payback: 69.0 billion won ($51.3 million USD) of annual subcontracting cost, growing, against a phased 200 billion won ($148.6 million USD) of owned capacity. On this view the only real question is construction timing. The positioning reading. Cosmecca is buying the right to say yes to volumes it currently has to decline or farm out, which is how an ODM moves from being a vendor to being a partner. On this view the capacity is a sales instrument, and utilisation in 2027 matters less than the conversations it enables in 2026. The cycle reading. Korean ODM capacity is being added across the sector simultaneously, at the top of an export cycle, against an indie client base with high churn. On this view the industry is collectively building the oversupply that will compress everyone's pricing in 2028, and the phased drawdown is the only thing that distinguishes prudence from exposure. What to watch next Three specific things, in order of when they will be visible. The 2026 annual report, due next spring, will show whether the outsourced processing cost line actually inflects or simply keeps climbing while construction proceeds. That single line is the thesis. Cosmecca's utilisation disclosure through 2027 will show whether the first Ochang phase fills. A new skincare plant running below capacity in a boom year is a much louder signal than the same plant running below capacity in a slow one. And the composition of the order book behind it. If Cosmecca is internalising production to serve a broader base of mid-sized and multinational accounts, the leverage is a growth cost. If it is internalising production to serve the same indie cohort faster, it has bought a fixed asset to serve a variable customer — and the disclosure worth reading will be the one filed in 2028, not this one.

On 8 September 2026 in Paris, Cosmax and L'Oreal signed a memorandum of understanding covering three areas of cooperation. The third is the development of new formulations and product formats drawn from the Korean beauty market and Korean consumer trends. No contract value, no volume and no term appears anywhere in the announcement. The world's largest beauty group did not sign for Korean capacity. It signed for Korean judgment about what a product should be. Twenty-two years separate the first stage on this line from the third: supply in 2004, ingredients in 2023, formulation in 2026. What exactly did Cosmax and L'Oreal sign in Paris? The signatories were Choi Kyung, vice chairman and chief executive of Cosmax, and Nicolas Hieronimus, chief executive of L'Oreal Group. Korea's Minister of Trade, Industry and Energy, Kim Jung-kwan, and a French trade envoy attended as witnesses. The signing was timed to the 140th anniversary of diplomatic relations between Korea and France. A memorandum of understanding is a signed statement of intent that creates no purchase obligation on either side. Korean trade press, reporting Cosmax's announcement, set out three areas. The first is joint research and development of products for global markets, drawing on L'Oreal's beauty science and consumer insight. The second is the discovery and development of innovative cosmetic ingredients and active substances — actives being the components that carry a product's functional claim, as distinct from the base that carries them. The third is the development of new formulations and product formats inspired by Korean beauty market and consumer trends. What the announcement does not contain is as informative as what it does. There is no disclosed value, no volume commitment, no term, no exclusivity clause and no statement on who owns jointly developed intellectual property. L'Oreal's own press-release page carries no corresponding announcement; the news moved from the Korean side. Why does the third area matter more than the first two? The first two clauses are ordinary supplier-development language. Every large beauty group runs joint ingredient work with its manufacturing partners, and has for decades. Ingredients and actives sit upstream of the product: they are molecules with a demonstrated effect, and sourcing them from a partner changes nothing about who decides what gets made. The third clause moves the boundary. Formulation is the decision about what a product physically is — the texture, the delivery format, the sensory behaviour on skin, the sequence in which a consumer uses it. Product format is the decision about what the object is at all: a stick, a cushion, an ampoule, a sheet. Those decisions have historically belonged to the brand owner, because they encode a reading of the consumer. Writing that responsibility into a document with a supplier names the supplier as a source of consumer interpretation. The asymmetry is visible in the numbers. L'Oreal reported 2025 sales of €44.05 billion, up 4.0% on a like-for-like basis, with research and innovation spending of €1,380.6 million, or 3.1% of sales. A group with that research base has signed a document stating that a Korean manufacturer is where new formulation concepts come from. How did a 2004 supply account become a 2026 formulation brief? On Cosmax's own account, as carried by Korean trade press, the relationship began in 2004 with product supply. In 2023, according to the same company account, the two signed a memorandum covering joint research into skin microbiome ingredients and the development of environmentally sustainable formulations. The 2026 document adds formulation and format planning. Three rungs in twenty-two years, each one further from the factory floor. Supply is a capacity relationship. Ingredient research is a science relationship. Formulation and format planning is a product-definition relationship. The direction of travel is single and it does not reverse. The quoted language from both executives, as rendered in English by the Korea Herald, tracks that reading. Choi framed the agreement as building on more than twenty years of accumulated trust to create the next generation of innovation led by K-beauty. Hieronimus framed it as combining respective strengths to deliver a new level of beauty experience to consumers worldwide. Neither statement mentions manufacturing volume. Each rung is further from the factory floor than the one below it; only the top rung touches what the product is. What does Cosmax hold that a European contract manufacturer does not? The scale figures explain the direction. Korean business press reported in August 2026 that Cosmax produces around 3.5 billion units a year, serves roughly 5,000 client companies, operates 19 plants, employs more than 1,100 research staff across the group, and develops more than 8,000 new formulations annually. Cumulative production of cushion compacts since 2013 stands at 900 million units. The plant capacity is replicable. The 8,000 formulations a year across 5,000 clients is not. That volume produces a continuously refreshed record of which textures sold, which formats died on shelf, and which consumer claims held up in a market that reprices novelty every quarter. A company cannot buy that record. It accumulates only by shipping failures at scale, and Korea's fragmented indie brand sector generates failures at a rate no single European brand house can match. The financial position underneath is solid rather than spectacular. Cosmax reported 2025 consolidated revenue of 2.399 trillion won (about $1.79 billion, converted at 1,337 won per dollar, the rate on 9 September 2026), up 10.7%, with operating profit of 195.8 billion won (about $146 million), up 11.6%. Korea's Ministry of Food and Drug Safety ranked Cosmax the largest ODM by domestic production for 2025 at 1.61 trillion won (about $1.20 billion). ODM stands for original development manufacturing: the supplier designs the product as well as making it, in contrast to OEM, where the supplier builds to the customer's design. ⓒCOSMAX Why is L'Oreal acquiring Korean judgment through several channels at once? The MOU is one of three procurement routes running in parallel. L'Oreal bought brand equity outright: 100% of Nanda Co., owner of Stylenanda and 3CE, announced in May 2018, and Gowoonsesang Cosmetics, owner of the dermatological brand Dr.G, announced in December 2024 at an undisclosed price. It buys consumer signal through programmes: L'Oreal Korea runs a generative-AI content laboratory and an open-innovation programme with Korea's Ministry of SMEs and Startups, and its Korean digital marketing head told ZDNet Korea in August 2026 that Korean consumers function as the world's most trend-sensitive early adopters, returning fast and refined feedback. The Paris memorandum adds the third route: formulation by contract. Equity, programme and supply agreement are three different instruments pointed at the same input. That is what a group does when it has concluded the input is structural rather than seasonal. The national context sharpens it. Korea exported $11.4 billion of cosmetics in 2025, up 12.2%, ranking second worldwide behind France at $24.3 billion and ahead of the United States at $10.8 billion, with shipments reaching 202 countries against 172 the year before. The world's largest beauty group is headquartered in the country that ranks first, and it has signed a document sourcing product ideas from the country that ranks second. ⓒCOSMAX If the manufacturer writes the formula, where does brand differentiation sit? This is the question the announcement does not answer, and Korea's own market shows the end state. Domestic cosmetics production reached 17.94 trillion won in 2025, up 2.3%. The brand tier and the manufacturing tier are formally separate: brand owners register as responsible distributors, and thousands of them commission from a small number of ODMs drawing on shared formulation libraries. When two competing products originate from adjacent shelves in the same sample library, they compete on story, distribution and price. The formula is not the moat. The counter-position is that the brief is the moat. A brand that writes a sharper brief extracts a better formula from the same supplier, and the first clause of this memorandum states that L'Oreal's beauty science and consumer insight feed the joint work. On that reading L'Oreal has not outsourced product definition; it has bought a faster instrument for executing definitions it still owns. Which reading holds depends entirely on a term the memorandum does not disclose. If Cosmax retains the right to sell an adjacent version of a co-developed formulation to any of its other clients, the arrangement is a speed advantage with a short half-life. If L'Oreal holds exclusivity on the output, it has converted a supplier's accumulated judgment into a proprietary asset at a fraction of the cost of acquiring the supplier. What does a memorandum with no numbers actually commit anyone to? Nothing enforceable in commercial terms. Documents of this shape create options: a defined scope of conversation, a public signal to both companies' markets, and a framework for contracts that follow. The disclosed content is intent and subject matter. The undisclosed content is money, volume, duration, exclusivity and ownership. The diplomatic staging supplies weight the commercial terms do not yet carry. Two governments witnessed the signature at a bilateral anniversary summit, which raises the cost of quiet abandonment for both parties. That is a real constraint, and it is not the same thing as a purchase order. ⓒCOSMAX What does this settle about where value sits in beauty manufacturing? Three readings sit side by side, and the industry has not chosen between them: The supplier reading: Interpretation is the scarce input and assembly is not, so the ODM tier is climbing into work the brand tier used to guard, and pricing will follow the climb. The brand reading: Outsourcing formulation converts a durable internal capability into a rented one, and any brand that rents it competes with every other tenant of the same landlord. The structural reading: Neither position is stable on its own, because the margin follows whoever writes the brief and whoever owns the resulting intellectual property, and those two roles are separable. What the Paris document establishes is narrower and harder to argue with. A group with €1.4 billion of annual research spending has put in writing that a manufacturer in Seoul is a source of what products should be, not merely of the products themselves. The areas are named. The owner of the output is not. The contract that follows this memorandum will name one, and that is the document worth reading.

Along the quiet, serene coastline of Santa Barbara, a revolution was brewing that would upend the beauty industry. Started in 2014 out of Dean Christal’s garage, this movement was destined to make noise: it directly challenged "hair damage"—a barrier the beauty world had accepted as inevitable for decades. Garages are cradles for industry disruptors. Just as Steve Jobs launched Apple in his parents' garage to usher in the PC era, Dean prepared to flip the professional haircare industry on its head from his own oil-stained floor. The age-old business axiom held true once again: single-minded obsession nurtured in isolation can reshape entire markets. In a vintage-style workshop filled with tools and scientific equipment, a man in a denim shirt is deeply focused on a chemistry experiment, ⓒinhoocho.com The Problem Dean Christal was an industry veteran who understood the inner workings of the beauty market better than most. Coming from a family steeped in the hair business, he pinpointed the exact pain point troubling stylists worldwide: the dreaded damage and breakage caused by chemical treatments like perms and bleaches. The industry consensus at the time was simple: to get vibrant or platinum blonde hair, you had to sacrifice its health. "Beauty is pain" was reframed in salons as "beauty requires destruction." Existing giants offered band-aid solutions—silicone and heavy oils that temporarily masked damage on the surface. Dean wanted a real fix that prevented structural destruction entirely. While beauty conglomerates poured billions into marketing illusions, Dean spent years combining ingredients in his garage late into the night, hunting for the key to fix structural hair flaws. Science Crashes the Salon Dean didn’t initially set out to create a brand-new "hair resuscitation" category. He simply wanted a silicone-based oil to rival Moroccan Oil. Everything changed when he met Dr. Craig Hawker, a world-renowned chemist at UC Santa Barbara. Dr. Hawker and his colleague Dr. Eric Pressly were authorities in polymer science and materials engineering—with zero prior ties to the beauty industry. When Dean explained how hair breaks down, the two scientists viewed it through pure molecular chemistry. Just as Roman concrete stood the test of time through an unexpected blend with volcanic ash, the beauty industry’s breakthrough came from scientists speaking an entirely different language. To them, hair was a matrix woven together by disulfide bonds—tiny molecular bridges. Strong alkaline chemicals sever these bridges, causing the structure to collapse. Within a day of hearing Dean’s problem, the chemists posed a straightforward hypothesis: construct a new molecular link to rejoin those broken bonds. ⓒOlaplex When Dean begged them to stop hair from melting off, they responded with casual scientific logic: "Why not just place a new molecular bridge between the broken bonds? It’s basic structural reinforcement." Chemical Proof, Not Magic Their hypothesis birthed Olaplex’s core ingredient: Bis-Aminopropyl Diglycol Dimaleate. Instead of coating the hair strand like traditional treatments, this active compound penetrates deep into the cortex. It seats itself between broken sulfur ($S$) bonds, acting as a sacrificial bridge that locks both sides back together. It was a cast for broken bones—a needle repair for a torn net. The moment Dean held the formula, he knew it was a game-changer. Olaplex birthed the category of fundamental hair repair, signaling the end of superficial mask treatments. Miracles unfolded directly in salons when colorists mixed this clear liquid straight into harsh bleaches. Instead of snapping, hair came out stronger. Olaplex created a multi-billion-dollar market behind a single active ingredient and one core patent. Consumers stopped falling for glossy branding; the physical reality of restored hair elasticity elevated Olaplex from a product to a near-religious staple. A stylist expertly analyzes a client's hair texture and condition in a modern, vibrant salon, preparing for a personalized hair treatment, ⓒinhoocho.com The Hollywood Breakthrough While the theory was sound, the market was skeptical. Tired of false claims, consumers were wary of "miracle" hair products. Skip the PR agencies, Dean went straight to the source: Hollywood celebrity colorist Tracey Cunningham, whose clients included Gwyneth Paltrow, Jennifer Lopez, and Kim Kardashian. Tracey tested the sample on a client the very next day. The result was remarkable. Hair that typically turned straw-brittle after repeated bleach sessions retained its elasticity and shine. Overjoyed, Tracey called Dean: "Dean, what is this stuff? It’s absolute magic! I’m never coloring without it again." Word from an industry titan proved far more powerful than any ad campaign. Three stylized portraits of women with wavy brown and blonde hair are set against a geometric patterned background, ⓒinhoocho.com The Instagram Engine Olaplex bypassed traditional media advertising completely, leveraging the visual boom of Instagram in 2014. Stylists globally began posting unedited "Before & After" photos showcasing drastic hair transformations. Clients began walking into salons showing phone screens, demanding the exact treatment they saw online. Olaplex flipped the dynamic—demand was driving supply. Within four months of launching, Olaplex was in 7,000 salons; six months after signing global distribution deals, that number surpassed 100,000, pulling in tens of millions in revenue. Olaplex War with a Titan: L'Oréal Fast growth invited corporate friction. In 2015, L'Oréal approached Olaplex with an acquisition offer. During due diligence, Olaplex shared confidential trade secrets, patented mechanisms, and proprietary formulas. Negotiations ultimately broke down. Shortly after, L'Oréal launched products containing hair-bonding technology strikingly similar to Olaplex's core mechanism. Olaplex sued, alleging patent infringement and trade secret theft. Period Litigation Outcome 2019 (District Court) Jury sides with Olaplex; orders L'Oréal to pay $91M in damages. 2021 (Appeals Court) Federal Circuit reverses verdict, ruling in L'Oréal's favor. Settlement Phase Long-term lawsuit ends in a confidential settlement. While Olaplex proved a startup could stand up to a conglomerate, losing exclusive enforcement in court dissolved a key legal moat, allowing competitor copycats to enter the market. Stumbling Blocks: The Test of Safety and Market Shifts By 2023, Olaplex faced significant backlash on the very platform that built it: social media. Class-Action Lawsuit: Posts alleging hair breakage and scalp irritation spread online, leading 28 consumers to file a class-action lawsuit. EU Ingredient Regulation: Lilial (butylphenyl methylpropional), used as a fragrance ingredient, was banned in the EU due to reproductive toxicity concerns. Olaplex immediately released updated formulations without Lilial and published extensive third-party clinical testing data showing product safety. The court eventually dismissed the class-action suit due to a lack of direct causal evidence linking the products to individual hair damage. Despite legal vindication, public sentiment cooled. Olaplex’s stock fell roughly 90% from its peak. Compounding the trouble, co-inventor Dr. Eric Pressly departed to launch a competing brand, Epres, introducing next-generation bonding technology. Olaplex The Henkel Acquisition: A Strategic Pivot To recover, Olaplex brought in new management, dialed back influencer marketing, and refocused on building relationships directly with professional hairstylists through clinical proof. This refocusing caught global attention. In March 2026, German consumer goods giant Henkel announced its acquisition of Olaplex for $1.4 billion. Though critics pointed out the valuation drop from its 2021 IPO peak, Henkel targeted the underlying core asset: Olaplex's pioneer bond-building technology and brand equity. Combined with Henkel’s global distribution network and capital, the acquisition serves as a strategic retreat designed to stabilize and rebuild long-term market dominance. Reconnecting the Pieces Olaplex's 12-year journey mirrors the reality of modern business. It fused two completely separate domains—molecular science and haircare—bridged the gap between professional salons and everyday consumers, and navigated immense corporate and legal battles. More than just a trend, Olaplex shifted the industry paradigm from temporary surface coating to fundamental structural repair. Backed by global infrastructure, its foundational science continues to shape the future of hair technology. Olaplex

ⓒCarol's Daughter A Niche in the Kitchen: Authenticity Unlocks the Market In the late 1980s, Lisa Price straddled two completely different worlds. By day, she worked on the fast-paced, glamorous set of The Cosby Show in New York. By night, she transformed into an experimentalist, wrestling with essential oils on her cramped Brooklyn kitchen counter. Her kitchen became a lab not out of a casual hobby, but out of absolute cosmetic marginalization. At the time, the beauty industry treated Black women’s hair purely as something to be "fixed." Mass-market shelves were packed with harsh chemical relaxers designed to force tightly coiled hair into submission. In a market where sleek, straight hair was the default standard, Black women had to endure scalp burns to tame their texture or give up on haircare altogether. Products that actually nourished and hydrated natural Black hair textures simply did not exist. Lisa stepped right into this massive void. Using a kitchen mixer, she blended dense, nutrient-rich fats like shea butter, almond oil, and cocoa butter to craft a moisturizing cream tailored specifically for Black hair. The scent was equally distinct. While existing products reeked of harsh chemicals, Lisa’s creams gave off a warm, sweet, natural aroma—like fresh bread straight out of the oven. The brand's identity crystallized during a brief conversation with her mother, Carol. Pondering a name that reflected her true self, her mother offered a dry yet brilliant piece of advice: "You’re my daughter—what better name is there than that?" That single exchange elevated a simple cosmetic line into a powerful narrative: a gift from a mother to her daughter. In 1993, Lisa stepped into the marketplace with just $100 and a sign bearing her mother’s name: Carol’s Daughter. Starting from a weathered stall at a Brooklyn flea market, this "kitchen-made cream" sold out almost instantly. There was no sleek packaging or grand advertising, but customers recognized it immediately: here was a product that didn't belittle their struggles, but genuinely understood their natural beauty. ⓒCarol's Daughter The Illusions of "Handmade" Meet Manufacturing Limits The secret formula Lisa discovered was more than a simple recipe. She pinpointed a fundamental truth: tightly coiled 4C hair naturally struggles to retain moisture due to its physical structure. To solve this, she relied on high concentrations of fats like shea butter and cocoa butter as her core ingredients. When this rich cream was featured on The Oprah Winfrey Show in 2002, it instantly became the answer to a nationwide craving. The response was explosive—crashing the website and pushing annual sales past $2 million almost overnight. This dramatic rise caught the eye of heavy-hitting investors, including Will Smith, Jay-Z, and Jimmy Iovine. In 2005, they injected $10 million into the company to scale Carol’s Daughter into a global brand. Yet, as massive capital poured in, Lisa’s pride in her "kitchen-crafted handmade" roots crashed headfirst into the reality of mass production. Ratios that worked perfectly in small batches at home began separating or spoiling inside massive, thousand-liter factory vats. Maintaining high levels of natural ingredients shortened shelf life, while adding chemical stabilizers to fix the issue threatened to compromise the brand’s core identity. Lisa stubbornly insisted on premium natural ingredients to preserve authenticity, but this resulted in a double whammy: soaring, uncontrollable production costs and erratic product quality. While the brand remained fixated on sensory descriptions and captivating scents, the market’s verdict turned harsh. Upstart competitors like SheaMoisture swept in, using precise manufacturing engineering to deliver consistent efficacy. Customers who initially bought in for the captivating scents began turning away when they saw no real improvement in their hair's health. Ultimately, the vague value of "authenticity" lost its edge to the precision of production engineering, costing the brand its market leadership. ⓒCarol's Daughter Hollywood Capital Sparks a "Bubble at Its Peak" Hungry for quick returns, the new investors pressed hard for rapid monetization. Lacking corporate management experience, Lisa buckled under the pressure. Without proper location analysis, the brand opened a string of high-rent, flagship retail stores in prime urban areas like Manhattan, Harlem, and Chicago. Supported by star-studded launch parties and heavy marketing leverage from celebrity investors, the initial splash was huge—but short-lived. Repeat purchases simply couldn't cover the crushing overhead and payroll costs. To make matters worse, only 20% of their bloated 300+ SKU catalog actually turned a profit. The remaining 80% sat on store shelves and in warehouses, languishing past their expiration dates and suffocating the company’s cash flow. By 2010, the financial cracks became impossible to hide. Flagship stores hemorrhaged money every month. Lisa stayed afloat through aggressive loans and secondary funding, but the drain from unprofitable retail locations ran too deep. In April 2014, Carol’s Daughter filed for Chapter 11 bankruptcy protection in New York. As then-CFO John Elmer conceded in court, liabilities overwhelmingly outpaced assets, and running the physical stores independently had reached a breaking point. The bankruptcy filing was a painful moment for Lisa. She was forced to close five of her seven beloved stores immediately and lay off 70% of the team who had built the brand alongside her. In the wake of Hollywood capital's departure, Lisa was left to face her managerial missteps and watch her brand crumble—a sobering reminder that emotional expansion cannot override cold financial realities. ⓒCarol's Daughter L’Oréal’s Lifeline: A Drastic Corporate Diet When news broke in October 2014 that L’Oréal USA had acquired the bankrupt Carol’s Daughter, public reaction was icy. Members of the Black community accused Lisa Price of selling out to a white-owned conglomerate. For Lisa, however, L’Oréal wasn't a selling out—it was the only system capable of rescuing her falling business, her absolute last lifeline for survival. Upon acquiring the brand, L’Oréal brought a cold scalpel of data and efficiency to Lisa's intuition-driven management style. Their immediate directive was uncompromising: restructure the entire product line based strictly on performance. L’Oréal ruthlessly cut unprofitable body care items and niche scents Lisa was personally attached to, scaling the catalog down to roughly 70 core, market-proven haircare products. The original lineup was slashed in half overnight. The operational overhaul went even deeper. L’Oréal restricted new product launches and mandated that all raw materials and manufacturing processes comply with L’Oréal’s global corporate standards. They shut down every chronically unprofitable flagship store, shifting distribution exclusively to mass retail partners like Target to maximize accessibility and lower overhead. While Lisa retained her title as founder and President, real decision-making power was absorbed into L’Oréal’s master spreadsheets. Under L’Oréal, Carol’s Daughter achieved widespread accessibility and commercial profitability. But the cost was steep. The personal warmth and grass-roots community connection Lisa had cultivated from her kitchen were steadily diluted inside a corporate manual. To L’Oréal, Carol’s Daughter was less a passion project and more a strategic asset to capture market share in the multicultural beauty space. While corporate capital saved the brand from extinction, the founder’s autonomy and the brand’s local, artisanal charm were pushed into the background. Lisa Price, ⓒCarol's Daughter L’Oréal’s Exit or the Founder’s Reclamation? In March 2025, the beauty industry was blindsided once again. L’Oréal announced it was reselling Carol’s Daughter back to a partnership group that included founder Lisa Price. While framed publicly as a triumphant return to its independent roots, a closer look reveals a strategic divestment by L’Oréal, cutting losses after recognizing the brand’s growth ceiling. While L’Oréal’s hyper-efficient infrastructure stabilized profits, it gradually eroded the brand's core engine: its deep community bond and loyal indie fandom. L’Oréal ultimately concluded that Carol’s Daughter had lost its unique appeal in the mass consumer market. Inside a homogenized corporate portfolio, the brand's identity had faded, leaving little room for explosive future growth. Realizing this, L’Oréal opted to divest at a time when the "Black-Owned" identity carried maximum marketing value, allowing the brand to return to its roots. Now, Lisa Price faces a critical test. This reclaimed "Black-Owned" title cannot remain a nostalgic marketing point as it once was. The brand’s survival hinges on her ability to retain the cold operational efficiency left behind by L’Oréal while modernizing the genuine authenticity originally tied to her mother’s name. The story of Carol’s Daughter carries a clear lesson: a founder’s passion can launch a business, but only cold numbers and flexible adaptation to market realities will keep it alive. Lisa Price’s journey—stepping back from individual stubbornness, absorbing a corporate infrastructure, and ultimately reclaiming her brand's sovereignty—is no longer just a badge of honor from the past. Moving past the era of the romantic indie founder, she now faces the ruthless reality of a CEO who must prove her leadership through performance. ⓒCarol's Daughter

Target Beauty Studio Opens: A New Era for K-Beauty in the U.S. Target Beauty Studio opens on 10 September in more than 600 U.S. stores, replacing the Ulta Beauty at Target shop-in-shops that closed on 16 August. Target's announcement highlights six Korean brands under two explicit K-Beauty headings and mentions a seventh Korean brand, Eqqualberry, under curated skincare. For a Korean brand, the label it receives is a bigger commercial fact than the mere listing itself. What is Target Beauty Studio? Target Beauty Studio is a new specialty beauty format launching on 10 September 2026 in over 600 Target stores and on Target.com. It will carry more than 1,600 products from 90 prestige, emerging, and global brands. Notably, more than two-thirds of these brands are new to Target. This new format succeeds the Ulta Beauty at Target partnership, which lasted nearly five years and ended on 16 August. Target is converting the same spaces—approximately 1,000 square feet each—across more than 2,000 U.S. stores into a format it fully controls. NewBeauty aptly described this transition: Target now has "full control over the assortment and merchandising it never had under the Ulta deal." Amanda Nusz, Target's Senior Vice President of Merchandising, Essentials, and Beauty, called Beauty Studio "a powerful example of how our merchandising authority comes to life through an elevated guest experience." From a supplier's perspective, this shift is significant. For five years, the buying decisions in these spaces were made by beauty specialists. Now, they are made by a mass merchant's merchandising organization, which has clearly indicated that its authority is paramount. Which Korean Brands are Featured in Target Beauty Studio? Target's announcement lists 26 of the 90 brands, revealing six Korean names under two distinct headings: "K-Beauty Cosmetics Favorites" — Amuse, Kaja, and Rom&nd. "Top Skincare Discovery Brands" — Dr. Melaxin, Purito Seoul, and Sungboon Editor. It's essential to note that six is merely a starting point. Since only 26 names were published, the complete count of Korean brands remains unknown from the release. Anyone quoting a total should refer to Target's own brand list for accuracy. Why Does Eqqualberry Matter? Eqqualberry is significant because Target did not categorize it as a Korean brand. Founded in Seoul and launched in 2023, Eqqualberry produces its products in Korea. However, in Target's announcement, it appears under curated skincare, alongside brands like Clearstem, First Aid Beauty, and Sunday Riley—not under either K-Beauty heading. This categorization is not an oversight; it is a critical detail in the announcement. Being placed in the K-Beauty group allows a Korean brand to benefit from category momentum and shopper expectations regarding price and novelty. In contrast, being categorized under curated skincare means it will be evaluated based on efficacy claims and price per milliliter. The second position is more challenging and potentially more lucrative. The national label serves as a merchandising category, and moving out of it is a strategic decision rather than a mere coincidence. One caution when interpreting Target's two Korean headings: favorites suggests proven sales performance, while discovery implies that a brand is being trialed. Therefore, I would advise treating the second group as being on trial and planning inventory and margins accordingly. This interpretation is my own, not something Target explicitly states, and the trade press has not interpreted it this way either. Cosmetics Business combined all six into a single list of K-beauty favorites. What Does a Beauty Studio Listing Actually Require from a Brand? Target has outlined its experience elements in detail. Here’s my interpretation of what each one demands from a supplier—none of the published sources discuss vendor economics, so consider this an operator's perspective rather than mere reporting. Dedicated Minis Assortment: Minis effectively create a second product line. This involves another fill run, additional packaging, and labeling, resulting in lower revenue per unit. They serve as a trial mechanism, typically funded by the brand. Product Testing Opportunities for Select Items: Testers are inventory that is never sold. Brands must purchase these units and replenish them as they deplete. Rotating Product Features: These include "Editors' Picks," "Most Loved," and "Standouts of the Season," along with a center table anchoring the space, starting with Lake & Skye's fragrances. Target states that the space "will evolve several times a year to showcase new brands, collaborations, and editorial-inspired moments." Rotation is not a risk here; it is part of the published design, and being included at launch does not guarantee inclusion during peak seasons. Dedicated Beauty Advisors: These advisors, dressed in signature uniforms, will offer personalized recommendations. This is the element I would value most and expect to be the hardest to achieve. It requires training materials, samples, and a memorable experience to stand out among 89 other brands vying for attention. Exclusive Target Circle Offers: Target presents these as a member benefit. In most retail agreements I have encountered, such offers are funded from somewhere, so it's crucial to clarify this before signing any contracts. Why is Target Launching This Now? Beauty is playing a pivotal role in Target's turnaround strategy. According to Cosmetics Business, Target's first-quarter 2026 sales were significantly boosted by a robust beauty performance, with beauty sales rising to USD 3.39 billion from USD 3.1 billion the previous year. Retail Dive reports total net sales for the quarter at USD 25.4 billion, reflecting a 6.7 percent increase. The beauty category is expanding across both price segments. Circana data cited by Retail Dive indicates that U.S. prestige beauty reached USD 17.1 billion in the first half of 2026, while mass beauty hit USD 39.2 billion, each up by 7 percent. Moreover, the distinction between mass retailers and beauty specialists is diminishing. Ally McPartland, a beauty and luxury manager at Kearney's consumer and retail practice, noted: "The line between 'mass retailer' and 'beauty specialist' is getting thinner from both directions." Kearney's upcoming Future of Beauty report reveals that approximately 45 percent of U.S. beauty shoppers are purchasing through mass channels, while 44 percent are shopping through specialty retailers. Walmart is also expanding its specialized beauty associate role to 425 stores. What Should a Korean Brand Monitor Moving Forward? Following the Ulta separation, Target's Executive Vice President and Chief Commercial Officer Rick Gomez stated that the company remains committed to a beauty experience "centered on an exciting mix of beauty brands with continuous newness, all at an unbeatable value," as reported by NewBeauty. Continuous newness is a promise to shoppers. For suppliers, it signals a commitment to longevity. Thus, the key metric is not merely the 600 doors opening on 10 September. Instead, it is how many Korean brands remain on that fixture in September 2027. Will those that endure still be categorized under K-Beauty, or will they have transitioned into categories where they are compared to brands like Sunday Riley rather than each other? The latter outcome is the one worth aspiring to. However, it is also the more costly one to support. In conclusion, understanding the dynamics of Target Beauty Studio is crucial for Korean brands aiming to penetrate the U.S. market. The strategic positioning, category placements, and the evolving landscape of beauty retail will dictate the success of these brands in this competitive environment.

Canada applies counter-tariffs to a list of American goods from 8 September 2026, and in cosmetics the list names exactly five tariff lines, all at 50%: perfume, lip make-up, eye make-up, manicure and pedicure preparations, and the residual hair line. Face and skin care preparations are not on it. Neither is shampoo. That single fact reverses the reading now circulating in the Korean trade press, because the categories the measure opens are not the categories Korean brands sell in Canada. What is a tariff line, and why is the list written in numbers? A counter-tariff is a duty a country imposes in response to another country's duty. It is not applied to "cosmetics" as a concept. It is applied to specific entries in a customs schedule, and those entries are code numbers. The codes come from the Harmonized System, the international product nomenclature that customs authorities everywhere use to classify goods. A four-digit code is a heading. A six-digit code is a subheading inside that heading. Countries then add their own digits underneath. This matters for one reason. A heading has a broad descriptive title, and the subheadings underneath it carve that title into narrower boxes. If you read only the heading title, you will believe the tariff covers far more than it does. If you read the subheadings, you find out what a customs officer will actually charge duty on. The Department of Finance published the list of United States products subject to counter-tariffs effective 8 September 2026. In the cosmetics chapter it names five tariff lines, all at 50%: 3303.00.00, perfumes and toilet waters; 3304.10.00, lip make-up preparations; 3304.20.00, eye make-up preparations; 3304.30.00, manicure or pedicure preparations; and 3305.90.00, preparations for use on the hair, other. Canada's counter-tariff schedule names five cosmetics lines at 50% — and the silences matter more than the entries. What is not on the list, and why does the absence matter more than the entries? Read what is absent. Heading 3304 runs on past those three lines into 3304.91, powders, and 3304.99, which in the Canadian customs tariff is where sunscreen preparations and face, hand and body creams and lotions sit. Neither is on the list. Heading 3305 opens with 3305.10, shampoos, then 3305.20 for waving and straightening preparations and 3305.30 for hair lacquers, before reaching the residual 3305.90. Only the residual was taken. A residual line is the box a classification system uses for everything in a heading it has not separately named — the "other" at the bottom of the list. It is not a minor category. In hair care it is where conditioner and hair serum end up, by elimination, because the heading names shampoos, waving preparations and lacquers and then stops naming things. So the effect on the shelf is this. Everything a Canadian consumer would call skincare was left alone. Shampoo, the single largest thing on the hair shelf, was left alone. Everything else in hair was taken, along with colour cosmetics, nails and fragrance. Ottawa did not tariff beauty. It tariffed five boxes inside beauty, and left the two biggest ones open. Where are Korean brands actually selling in Canada? Almost entirely in the boxes that were left open, which is why this matters. NielsenIQ's Canadian analysis has K-beauty sales growing 57% year on year in 2025, with Laneige, COSRX, Dr. Jart+ and Innisfree joined by newer arrivals including Beauty of Joseon, Skin1004, ma:nyo, Torriden and D'Alba Piedmont, some of them at triple-digit rates. The category over-indexes strongly among consumers aged 18 to 44. Over-indexing is a comparison, not a headcount: it means K-beauty takes a larger share of that age band's beauty spending than it takes of the market as a whole. It does not mean everyone buying is under forty-five, and it is worth being careful with, because the two get conflated constantly in trade coverage. Online accounted for more than 40% of those sales, well above the beauty average, and Amazon and Sephora together took nearly 40% of all K-beauty spend — with the physical growth concentrated in Sephora, Costco and selected ethnic grocery banners. Notice what that list is not. It is not a fragrance counter, a nail bar or a colour cosmetics wall. The Korean position in Canada is efficacy skincare, sold across a mix of online and specialty retail, and none of it sits in a category the tariff touched. Which Canadian beauty categories are actually growing? Set the schedule against Circana's Canadian first-half figures, published from Toronto on 11 August. Hair was the strongest category at +23%, driven by hair serum at +91%, daily rinse shampoo at +22% and conditioner at +20%. Skincare grew 6%, with masstige facial skincare brands up 22% through June and face sunscreen among the fastest-growing segments. Makeup rose 4%. Fragrance moderated to 1%. Masstige is a measurement bracket sitting between mass and prestige: mid-priced products that carry the claims and the finish of premium ones. It is the bracket most Korean skincare brands occupy in a Western market, whether or not they describe themselves that way, and it is the fastest-moving thing in Canadian skincare. Now lay the two documents over each other. The tariff hits fragrance hardest, the slowest-growing of the four categories Circana reports. It hits colour, which grew 4%. It cuts the hair aisle along a seam, catching the residual line and leaving shampoo alone. And it does not touch facial skincare at all, which is where Korean brands in Canada have actually built. The measure takes the residual hair line at 50% and leaves shampoo, named separately at 3305.10, outside it. So is this an opening for Korean brands, or not? It is an opening. It is just not the one being described. What opened is lip, eye, nails, fragrance and the non-shampoo half of the hair aisle. That is a real commercial opportunity and anyone who wants it should say so plainly, then build the product, the claim and the label for those categories — which are different products, different claims and different labels from the ones most Korean exporters currently ship to North America. What did not open is Canadian facial skincare, because it was never closed. I should be exact about the status of that claim. It is a shelf-level opening, and as I read it, it lands in the four aisles where Korean brands in Canada are thinnest. That is an argument about the schedule set against the channel evidence. Nobody has published a category-by-category split of Korean beauty sales in Canada, so treat it as a reading rather than as a measured fact — but the direction is hard to argue with once you have the two documents side by side. Why is a tariff a weak reason to enter a market? Because it hands you demand you did not earn, on a timetable you do not control. A price gap created by a tariff can be withdrawn by announcement, and Canada has done exactly that once already. It announced on 22 August 2025 that most of its retaliatory surtaxes on American goods would come off, effective 1 September 2025, keeping them only on steel, aluminium and automobiles. That is a year and a week before the schedule that starts tomorrow. Finance Minister François-Philippe Champagne has said the counter-tariffs match American levels. Matching is a posture that moves when the other side moves. It is designed to be reversible; that is the entire point of it. Follow that through to the shelf. A brand that wins a Canadian listing this quarter on relative price will be re-priced the moment the two governments settle, and will then be holding that listing on nothing else. The buyer who took you in because you were suddenly the cheaper option has no reason to keep you when you stop being it, and no story to tell their category manager about why they should. Entering on a tariff gap is not a strategy. It is a bet on two governments staying angry. What does Health Canada require before a product can be sold? This is the part that does not move, and it is where a Canadian launch actually gets decided. Health Canada requires a cosmetic notification for each product, due within ten days of the first sale in Canada. A notification is not an approval — nobody reviews your product and grants permission — but it is not optional either. Its own guide warns that failing to notify may see a product denied entry into Canada or removed from sale. Ingredients have to be checked against the Cosmetic Ingredient Hotlist, the published register of substances that are prohibited outright or restricted to certain concentrations and conditions. One nuance is worth carrying: Health Canada is careful to say the Hotlist is not exhaustive. Clearing the list is not the same thing as being compliant, and a formulation that passes a Hotlist screen can still fail the underlying regulations. For a Korean brand this is the point at which a contract manufacturer relationship starts to matter operationally rather than commercially. The people who can answer an ingredient question at concentration level, quickly, in writing, are the people who formulated the product — and if that is a third-party manufacturer, the answer arrives on their timetable, not yours. Three label elements must be bilingual and two need not; the notification and the label outlast the tariff either way. Which parts of a Canadian label have to be in both languages? Three of them, and this is the detail most often got wrong in export briefings. The label has to be bilingual in English and French for the product identity, the net quantity and any avoidable-hazard warnings. Those three carry a genuine translation and artwork requirement. Not everything does. The dealer's name and address may appear in English, French or both. And the ingredient list runs in INCI — the International Nomenclature of Cosmetic Ingredients, a single standardised naming system used across markets precisely so that ingredient names do not have to be translated. It does not have to be given twice. Knowing which three elements are actually bilingual, and which two are not, is roughly the difference between one artwork round and three. It is also, in practice, the difference between hitting a promised shelf date and missing it, because artwork revisions do not run in parallel with anything else — they queue. Why has bilingual labelling suddenly become political? Because it has just been fought over in public, and that changes how likely it is to be relaxed. When Prime Minister Mark Carney suspended negotiations with Washington on 21 August, his statement gave no detailed reasons. Over the following days he said the American side had pushed against Canada's bilingual labelling rule and against measures making French-language content discoverable on streaming services. The United States Trade Representative called the labelling account a fabrication. By 27 August, Ottawa said Washington had withdrawn its positions on language and culture. That exchange is contested and should be reported as contested. But however it is finally scored, one thing is settled: the rule survived it. A requirement that has just been the subject of a public argument between two governments is not a requirement anyone is about to quietly waive for a Korean serum. The asymmetry is simple. The tariff window may last a quarter. Bilingual artwork, an ingredient review against the Hotlist and a notification file take longer than that, and they are what a Canadian buyer asks for before asking the price. Toronto, ON, Canada What should a brand do about Canada this week? Circana has already described the durable entry, without meaning to. Alecsandra Hancas, its beauty and wellness industry analyst for Canada, said consumers there "are prioritizing products that deliver efficacy, support wellness goals, and provide an affordable form of indulgence", and the release says they are gravitating towards products that combine "clinical credibility, proven results, and accessible pricing". Read that second phrase as a procurement specification rather than a trend note and it says something concrete: bring a claims file. A claims file is the evidence pack behind what a product says about itself — the test method, the panel, the result, the scope of what was actually measured. It is what a Canadian buyer, and eventually a Canadian regulator, will ask to see, and it is the one asset a competitor cannot copy off your packaging. Masstige facial skincare grew 22% on that basis while sitting entirely outside the tariff schedule. That is the evidence that the growth was never about the border. So: two different answers for two different companies. If you sell colour, fragrance, nails or hair treatments, the opening that starts tomorrow is genuinely yours, and the work is to build for those categories rather than to retrofit a skincare pitch into them. If you sell facial skincare, nothing changed tomorrow — and that is the good news, because it means the thing you have been building is still the thing that wins.